LUN H. Lundbeck A/S

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Valby, Denmark, 9 May 2019 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Deborah Dunsire
2. Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,

auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial

instrument, type of instrument



Identification code
Shares



 



 



DK 0010287234
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s) Price(s) Volume(s)
    272.62 3,500
d) Aggregated information

- Aggregated volume

- Price
 
e) Date of the transaction 2019-05-09
f) Place of the transaction NASDAQ Copenhagen XCSE



1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Henrik Andersen
2. Reason for the notification
a) Position/status Member of the Board of Directors
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,

auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial

instrument, type of instrument



Identification code
Shares



 



 



DK 0010287234
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s) Price(s) Volume(s)
    287.90 3,500
d) Aggregated information

- Aggregated volume

- Price
 
e) Date of the transaction 2019-05-08
f) Place of the transaction NASDAQ Copenhagen XCSE

 

 

 

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

  • spouse or cohabitant
  • dependent children
  • legal entities in which the executive has a controlling influence.

Lundbeck contacts

Investors:

Palle Holm Olesen

Vice President, Investor Relations



Media:

Mada Kronborg

Senior Director, Corporate Communication



About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at . 

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18,1 billion in 2018 (EUR 2,4 billion; USD 2,8 billion).

For additional information, we encourage you to visit our corporate site  and connect with us on Twitter at  and via .

Attachment

EN
09/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on H. Lundbeck A/S

Rune Majlund Dahl
  • Rune Majlund Dahl

Lundbeck (Buy, TP: DKK44.00) - New guidance structure

Q4 sales and EBITDA missed our forecasts as strategic brands sales were soft. The 2024 guidance was also soft but in a new better structure, we believe, for revenue growth of 7–10% CER (-4% in DKK) and adj. EBITDA growth of 10–16% in CER (-9% in DKK). We also note the decision to move Lu AF82422 into phase III in MSA. We reiterate our BUY and DKK44 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Lundbeck (Buy, TP: DKK44.00) - Focus on guidance and M&A

We expect Lundbeck to reach the high end of its 2023 guidance, and forecast Q4 revenue of DKK5,111m and adj. EBITDA of DKK929m. For 2024, we look for continued good growth across strategic brands (we forecast 12.9%), and we believe investors will focus on the M&A agenda to strengthen the late-stage pipeline. We expect the 2024 guidance to be for revenue of DKK21.0bn–21.6bn and EBITDA of DKK5.7bn–6.3bn. We reiterate our BUY and DKK44 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Lundbeck (Buy, TP: DKK44.00) - Focus on progressing the pipeline

At Lundbeck’s R&D event in London yesterday, focus was on pipeline progression and its R&D commitment. Lundbeck believes two of the six discussed pipeline candidates could reach the market in 2029. In the coming years, we expect increased focus on acquisitions to strengthen the late-stage pipeline to facilitate timely new product launches before the ‘patent cliff’ (we estimate in 2029). We reiterate our BUY and DKK44 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Lundbeck (Buy, TP: DKK44.00) - R&D event ahead

Despite a Q3 revenue miss, Lundbeck has narrowed its 2023 revenue guidance to DKK19.8bn–20.1bn but raised adj. EBITDA to DKK5.6bn–5.8bn, reflecting the Q3 beat on lower R&D costs. We expect the R&D event due on 30 November to be an eye-opener, as we believe most investors have assigned limited value to the pipeline. We reiterate our BUY and target price of DKK44.

Rune Majlund Dahl
  • Rune Majlund Dahl

Lundbeck (Buy, TP: DKK44.00) - Another increase to guidance likely

We expect Q3 top-line growth of 8.7% YOY (consensus 7.8%), driven by strategic brands, for which we forecast sales growth of 10.5% YOY, and an EBIT margin of 16.5% versus consensus of 15.5% (results due at 07:00 CET on 8 November). We expect the company to raise its 2023 guidance for revenue to DKK19.9bn–20.2bn (from DKK19.5bn–20.1bn) and for adj. EBITDA to DKK5.4bn–5.7bn (from DKK5.2bn–5.6bn). We reiterate our BUY and have raised our target price to DKK44 (41).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch